On 21 April, the TGA approved Moderna Australia’s application to transition its COVID-19 vaccine, SPIKEVAX (elasomeran), from provisional to full registration. This is the first COVID-19 vaccine to have received full registration.

As with all medicines, the TGA’s assessment was rigorous, independent and based on evidence. The safety and efficacy of SPIKEVAX  is also supported by real-world use in millions of people worldwide, providing reassurance about the safety of these vaccines. Vaccination remains the most effective way to protect yourself from serious disease, hospitalisation and death.

https://www.tga.gov.au/news/media-releases/modernas-covid-19-vaccine-spikevax-receives-approval-full-registration